DME

Capital.com's Client Trading Volumes Surpass USD1 trillion in 2023

Retrieved on: 
onsdag, maj 8, 2024
Federal Reserve, Federal, Gold, DME, Growth, Cryptocurrency

LIMASSOL, CYPRUS, May 8, 2024 - (ACN Newswire) - Capital.com, the high-growth global trading platform and fintech group, has today announced that total client trading volumes reached more than $1.2 trillion in 2023.

Key Points: 
  • LIMASSOL, CYPRUS, May 8, 2024 - (ACN Newswire) - Capital.com, the high-growth global trading platform and fintech group, has today announced that total client trading volumes reached more than $1.2 trillion in 2023.
  • This is a rise of 53% from a year earlier and marks the first time client trading volumes have breached the $1trn mark since the company's inception in 2016.
  • The vast majority of trading volumes came from clients in the Middle East, followed by Germany, Italy and the Netherlands.
  • Over the same period, trading volumes in commodity markets accounted for 58% of total volumes traded, making it the second most heavily traded market by volume on the Capital.com platform.

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
torsdag, maj 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
onsdag, maj 8, 2024
Science, FDA, AMD, Investment, DOI, Safety, OIS, Stuart, Florida, Food, Research, Cleveland Clinic, Growth, FACS, KOL, Therapy, Thomas Jefferson University, Eye, Wills Eye Hospital, Marketing, DME, Clinical trial, Associate, Diabetic retinopathy, ARVO, Plasma, Uveitis, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Key Points: 
  • The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data in the third quarter of 2024.
  • EyePoint plans to host an R&D Day on June 26, 2024 in New York City.
  • Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million.
  • Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million versus $29.2 million in the prior year period.

Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases

Retrieved on: 
onsdag, maj 8, 2024
AMD, Blood, Research, Diabetic retinopathy, Diabetes, Half-life, Disease, STZ, Patient, Macrophage, Hypertension, Macular degeneration, DME, Ageing, Permeability, Annual general meeting, VEGF, ARVO, DR

SACRAMENTO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, today announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases. The data was detailed in a poster presented by Aaron Kantor, Ph.D., Head of Translational Sciences at Therini Bio, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA, on May 7, 2024.

Key Points: 
  • SACRAMENTO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, today announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases.
  • Therini Bio has developed a potential first-in-class therapeutic monoclonal antibody, THN391, that is designed to selectively block fibrin-mediated neuroinflammation without interfering with fibrin’s coagulation properties.
  • In preclinical models of macular degeneration and diabetic retinopathy, THN391 and its analogs demonstrated effectiveness in protecting against vascular and neuronal degeneration.
  • “We are very encouraged by our data demonstrating the effectiveness of THN391 in rodent models of neurodegenerative ocular diseases,” said Joel Naor, M.D., Chief Medical Officer - Ophthalmology at Therini Bio.

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
onsdag, maj 8, 2024
Dexamethasone, Pain, State, Inflammation, Investment, Refractive surgery, Safety, NDA, OCS, Research, Cataract, DED, AON, Development, IND, Retina, ASCRS, Research and development, Patient, Society, Pharming, CHF, Genotype, DME, Bank statement, Clinical trial, Annual general meeting, Ophthalmology, Pharmaceutical industry

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points: 
  • The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
  • Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
    Snehal Shah, Pharm.
  • The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results

Retrieved on: 
måndag, maj 6, 2024
Society for Vascular Surgery, Total, Cellulitis, Lymphedema, Webcast, Retirement, TCMD, Patient, Operating cost, Head, DME, Quality of life, Growth, Video game

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024.
  • Gross profit in the first quarter of 2024 increased $2.0 million, or 5%, to $43.4 million, compared to $41.5 million in the first quarter of 2023.
  • Operating loss was $3.0 million in the first quarter of 2024, compared to $3.8 million in the first quarter of 2023.
  • Non-GAAP operating loss in the first quarter of 2024 was $1.7 million, compared to $2.2 million in the first quarter of 2023.

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
måndag, maj 6, 2024
Net, Skin, Investment, Solubility, Research, Diabetes, BioCryst Pharmaceuticals, Plasma, Injection, Webcast, Kallikrein, Prescription, Disease, Dehydration, Patient, Eye, Operating cost, Physician, Paratriathlon, EPS, Workforce, Infection, DME, Clinical trial, HAE, Diabetic retinopathy, Edema, Genetic disorder, GAAP, Netherton syndrome, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.
  • Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y).
  • Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures.
  • ET today to discuss the financial results and provide a corporate update.

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Retrieved on: 
måndag, maj 6, 2024
AMD, FDA, Safety, Retinal vasculitis, Conference call, Conference, Arm, Disease, TKI, Therapy, Patient, DME, Diabetic retinopathy, Endophthalmitis, Retina, Anti-VEGF, Pharmaceutical industry

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The data demonstrated that DURAVYU has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint. The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data.

Key Points: 
  • “The objective of the PAVIA trial was, for the first time, to evaluate DURAVYU as a potential treatment in a non-proliferative diabetic patient population,” said Jay Duker, M.D., Chief Executive Officer of EyePoint Pharmaceuticals.
  • I would like to thank the patients, the investigators and their site staff who participated in the PAVIA trial.
  • PAVIA is a 12-month, randomized, controlled Phase 2 clinical trial of DURAVYU in patients with moderately-severe to severe NPDR.
  • A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com .

Myomo Reports First Quarter 2024 Financial Results

Retrieved on: 
onsdag, maj 8, 2024
Robotics, Medical Devices, Health, Technology, Neurology, Biotechnology, Medicare (United States), Table, CMS, International, Investment, PIN, Growth, Webcast, Patient, Operating cost, Medicare, DME, ASP, GAAP

Myomo recognized revenue on 91 MyoPro units in the first quarter of 2024, up 14% compared with the same quarter a year ago.

Key Points: 
  • Myomo recognized revenue on 91 MyoPro units in the first quarter of 2024, up 14% compared with the same quarter a year ago.
  • Gross margin for the first quarter of 2024 was 61.2%, compared with 67.0% for the first quarter of 2023.
  • Operating expenses for the first quarter of 2024 were $6.2 million, an increase of 24% compared with the first quarter of 2023.
  • Adjusted EBITDA for the first quarter of 2024 was $(3.5) million, compared with $(2.5) million for the first quarter of 2023.

Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees

Retrieved on: 
måndag, maj 6, 2024
Robotics, Health, Medical Devices, Technology, Neurology, Health Technology, Health Insurance, CMS, Patient, Medicare, DSM-IV codes, DME, MYO, Health insurance

The amounts paid were based on the fees published by CMS for the Company's Healthcare Common Procedures Coding System (“HCPCS”) codes L8701 and L8702, which became effective on April 1, 2024.

Key Points: 
  • The amounts paid were based on the fees published by CMS for the Company's Healthcare Common Procedures Coding System (“HCPCS”) codes L8701 and L8702, which became effective on April 1, 2024.
  • All four regional DME MAC's have remitted lump sum reimbursements, and payments have been received for a number of patients of the Company and O&P providers based on the published fee schedule.
  • “We’re pleased to see that lump sum payments have been approved from all four billing regions so that Medicare beneficiaries also have equitable access to this life-changing technology,” stated Paul R. Gudonis, Myomo’s Chairman and CEO.
  • “We are also gratified by the interest we are seeing from clinical providers in the orthotics and prosthetics industry since one of our MyoPro Centers of Excellence providers had its first claim paid by Medicare.